Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus

被引:34
|
作者
Hong, Ying [1 ]
Rohatagi, Shashank [2 ]
Habtemariam, Bahru [1 ]
Walker, Joseph R. [2 ]
Schwartz, Sherwyn L. [3 ]
Mager, Donald E. [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[2] Daiichi Sankyo Pharma Dev, Edison, NJ USA
[3] Diabetes & Glandular Dis Clin, San Antonio, TX USA
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 48卷 / 06期
关键词
type 2 diabetes mellitus; metformin; pharmacokinetics; pharmacodynamics; mathematical modeling;
D O I
10.1177/0091270008316884
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The exposure-response properties of metformin were characterized in 12 subjects with type 2 diabetes mellitus. The time course of drug concentration and effects on fasting plasma glucose and lactic acid concentrations were used from a study in which subjects received 500 mg of metformin twice daily for 5 days followed by 850 mg twice daily for 5 days. Pharmacokinetic sampling included morning trough concentrations obtained on days 7 to 9 and rich sampling (15 time points) on day 10. Fasting plasma glucose and lactic acid concentrations were measured on days 0 to 10 and served as biomarkers of therapeutic effect and tolerability, respectively. A population pharmacokinetic/pharmacodynamic analysis was conducted using nonlinear mixed effects modeling. Metformin pharmacokinetics were described using a 1-compartment model with first-order absorption. Population mean estimates (relative standard error [RSE]) of clearance (CLIF) and volume of distribution were 79.0 L.h(-1) (6.8%) and 648 L (13.8%), respectively. Covariate analyses revealed that creatinine clearance (CLCR) significantly influenced metformin CLIF [CL/F = 79.0.(CLCR/80)(0.822)]. An indirect response model was applied to describe the antihyperglycemic effect of metformin. Population mean estimates (RSE) of baseline fasting plasma glucose and the drug concentration producing half-maximal effect were 241 mg.dL(-1) (4.6%) and 4.23 mg.L-1 (31.0%). An empirical linear model was used to describe a slight progressive increase in fasting lactic acid during metformin treatment with an estimated slope coefficient (RSE) of 0.0005 mM.mL.ng(-1) (38.1 %). Model evaluation by predictive check and non-parametric bootstrap analysis suggested that the proposed model is robust, and parameter values were estimated with good precision. Simulations suggested that the clinical utility of metformin was maintained over the dose range evaluated with respect to fasting plasma glucose and lactic acid response.
引用
收藏
页码:696 / 707
页数:12
相关论文
共 50 条
  • [21] Metformin and type-2 diabetes Mellitus
    Mata Cases, Manel
    ATENCION PRIMARIA, 2008, 40 (03): : 147 - 153
  • [22] Safety of metformin in Type 2 diabetes mellitus
    Baigent, C
    Peto, R
    DIABETIC MEDICINE, 1999, 16 (02) : 89 - 90
  • [23] Metformin in patients with type 2 diabetes mellitus and heart failure: a review
    Kulaczkowska, Zofia M.
    Wrobel, Marta
    Rokicka, Dominika
    Gasior, Mariusz
    Strojek, Krzysztof
    ENDOKRYNOLOGIA POLSKA, 2021, 72 (02) : 163 - 170
  • [24] Combined metformin and insulin therapy for patients with type 2 diabetes mellitus
    Ponssen, HH
    Elte, JWF
    Lehert, P
    Schouten, JP
    Bets, D
    CLINICAL THERAPEUTICS, 2000, 22 (06) : 709 - 718
  • [25] Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus
    Tseng, Chin-Hsiao
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [26] Secondary Metformin Monotherapy Failure in Type 2 Diabetes Mellitus Patients
    Weiss, Tracey
    Iglay, Kristy
    Verma, Priya
    Rajpathak, Swapnil
    Yang, Lingfeng
    Blonde, Lawrence
    DIABETES, 2019, 68
  • [27] Contraindications to metformin therapy among patients with type 2 diabetes mellitus
    Waleed M. Sweileh
    Pharmacy World & Science, 2007, 29 : 587 - 592
  • [28] Metformin and Risk of Hypertension in Taiwanese Patients With Type 2 Diabetes Mellitus
    Tseng, Chin-Hsiao
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (13):
  • [29] Metformin and lung cancer risk in patients with type 2 diabetes mellitus
    Tseng, Chin-Hsiao
    ONCOTARGET, 2017, 8 (25) : 41132 - 41142
  • [30] Efficacy of metformin on different adipocytokines in type 2 diabetes mellitus patients
    Hamdy, Naglaa
    Abdel-Gabbar, Mohamed
    Sakr, Hader I.
    Abdelaziz, Mohamed A.
    Kandeil, Mohamed
    Aziz, Ayman M. Abdel
    Ahmed, Osama M.
    EGYPTIAN PHARMACEUTICAL JOURNAL, 2024, 23 (02) : 207 - 215